Related Experiment Video
Updated: Apr 18, 2026

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
[Immune defects in multiple myeloma]
Multiple myeloma derives from the precursor cells of B lymphocytes, and it alters the host's immunity. It suppresses polyclonal antibody production, reduces CD4/8 ratio, and suppresses NK cells and dendritic cells. Myeloma cells and bone marrow stromal cells produce IL-6 and VEGF, which also alters the immunological microenvironment. While most anti-cancer agents suppress the host's immunity deeply, immunomodulatory drugs (IMiDs) activate T and NK cells, which induce anti-myeloma effects. Currently several bisphosphonates and anti-RANKL antibody are used to prevent skeletal-related events in myeloma, and these agents also have some impacts to the immune system. To enhance therapeutic strategies of myeloma, it is crucial to uncover the interactions of the immunological microenvironment and these agents in myeloma patients.
Multiple myeloma derives from the precursor cells of B lymphocytes, and it alters the host's immunity. It suppresses polyclonal antibody production, reduces CD4/8 ratio, and suppresses NK cells and dendritic cells. Myeloma cells and bone marrow stromal cells produce IL-6 and VEGF, which also alters the immunological microenvironment. While most anti-cancer agents suppress the host's immunity deeply, immunomodulatory drugs (IMiDs) activate T and NK cells, which induce anti-myeloma effects. Currently several bisphosphonates and anti-RANKL antibody are used to prevent skeletal-related events in myeloma, and these agents also have some impacts to the immune system. To enhance therapeutic strategies of myeloma, it is crucial to uncover the interactions of the immunological microenvironment and these agents in myeloma patients.
More Related Videos
05:32Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
Published on: January 7, 2019
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
Related Concept Videos
Disorders of Leukocytes
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
Differentiation of Common Myeloid Progenitor Cells
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
Multiple Sclerosis l: Introduction
Chronic Kidney Disease II: Clinical Manifestations